Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Balcinrenone PK in Hepatic Impairment
NCT06388616Phase 1Completed
- Sponsor
- AstraZeneca
- Start
- May 2024
- Primary completion
- Sep 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label trial of balcinrenone in chronic kidney disease (CKD) and heart failure (HF) (3 arms), sponsored by AstraZeneca. Primary endpoints: Area under plasma concentration-time curve from time zero to the last measurable concentration, Area under plasma concentration-time curve from zero to infinity and 1 more. Started May 2024; status: completed.
02
Drugs
balcinrenone
03
Conditions
chronic kidney disease (CKD)heart failure (HF)
Beyond the preview
Go deeper on NCT06388616.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06388616.